Rh Immunoglobulin (Anti-D): Prevention of Hemolytic Disease & Neonatal Jaundice

Introduction: Anti-D Immunoprophylaxis—Preventing Jaundice Before It Begins

Rh immunoglobulin (anti-D IgG) represents one of the greatest success stories in preventive medicine. Since its introduction in the 1960s, it has reduced the incidence of Rh hemolytic disease of the newborn (HDN) from approximately 1 in 100 Rh-negative pregnancies to less than 1 in 1,000 where prophylaxis is properly administered. In India, where 5-8% of the population is Rh-negative and approximately 1.2 million Rh-negative pregnancies occur annually, ensuring universal anti-D prophylaxis remains a critical public health priority.

Despite the availability of anti-D, Rh HDN continues to be a significant cause of severe neonatal jaundice in India due to inadequate prophylaxis coverage, particularly in rural areas, home deliveries, and following first-trimester pregnancy events. When prevention fails, the resulting severe neonatal jaundice requires intensive phototherapy, IVIG, and potentially exchange transfusion—interventions that carry significant morbidity, cost, and logistical challenges.

Mechanism of Action

How Anti-D Prevents Sensitization

During pregnancy and delivery, small volumes of fetal Rh-positive red blood cells can enter the Rh-negative mother's circulation (fetomaternal hemorrhage, FMH). Without prophylaxis, the maternal immune system recognizes the D antigen as foreign and produces anti-D IgG antibodies. These antibodies persist lifelong and cross the placenta in subsequent pregnancies to destroy Rh-positive fetal RBCs.

Anti-D immunoglobulin works through several mechanisms:

• Antigen clearance: Anti-D coats fetal Rh-positive RBCs in maternal circulation, targeting them for rapid splenic destruction before the maternal immune system mounts a primary response
• Antigen masking: Bound anti-D IgG shields the D antigen from recognition by maternal B cells
• Immune suppression: Anti-D triggers inhibitory FcγRIIB signaling on maternal B cells, suppressing antibody production
• Central inhibition: Reduces antigen presentation to T-helper cells, preventing T-dependent B cell activation

Indications for Anti-D Administration

Antenatal Indications

Timing/Event	Dose (mcg IM)	Notes
Routine antenatal prophylaxis (28 weeks)	300	FOGSI/NNF recommended for all unsensitized Rh-negative women
Amniocentesis/CVS	300	Within 72 hours of procedure
Antepartum hemorrhage	300	After any episode; may need repeat with recurrent bleeding
External cephalic version	300	Regardless of success
Abdominal trauma	300	Any significant abdominal trauma in pregnancy
First-trimester abortion/miscarriage	50-150	Lower dose sufficient before 12 weeks
Ectopic pregnancy	300	After surgical or medical management
Molar pregnancy	300	After evacuation

Postnatal Indication

• Standard postnatal dose: 300 mcg IM within 72 hours of delivery of an Rh-positive baby
• Large FMH: If Kleihauer-Betke test or flow cytometry indicates FMH greater than 30 mL whole blood, calculate additional anti-D: 10 mcg per mL of fetal blood
• Cesarean section: Higher risk of FMH; always give postnatal dose; consider Kleihauer test

Dosing Protocol: Indian Guidelines (FOGSI/NNF)

Standard Protocol

1. First antenatal visit: Blood grouping with Rh typing for all pregnant women. If Rh-negative, check indirect Coombs test (ICT) for existing sensitization
2. If ICT negative (unsensitized): Plan anti-D prophylaxis at 28 weeks
3. 28 weeks: Anti-D 300 mcg IM (single dose antenatal prophylaxis)
4. After delivery: Cord blood—baby's blood group, Rh type, and direct Coombs test
5. If baby is Rh-positive: Anti-D 300 mcg IM to mother within 72 hours
6. If baby is Rh-negative: No postnatal dose needed
7. Kleihauer-Betke test: Recommended after delivery (especially cesarean) to quantify FMH and determine if additional anti-D is needed

Available Anti-D Products in India

Product	Manufacturer	Dose Available	Approximate Cost (INR)
Rhoclone	Bharat Serums	300 mcg	1,800-2,500
Matergam P	Biotest AG	300 mcg	3,000-4,000
D-Gam	Bio Products Lab	300 mcg	2,500-3,500
Rhogam	Kedrion	300 mcg	3,500-4,500

When Prevention Fails: Managing Rh HDN

Recognizing Anti-D Prophylaxis Failure

Despite optimal prophylaxis, sensitization still occurs in approximately 0.1-0.3% of Rh-negative pregnancies. Anti-D prophylaxis failures and missed opportunities result in Rh HDN that presents as severe neonatal jaundice. Warning signs include:

• Positive indirect Coombs test in a previously unsensitized mother
• Rising anti-D antibody titers during pregnancy
• Fetal anemia detected on middle cerebral artery Doppler
• Hydrops fetalis on antenatal ultrasound
• Cord bilirubin greater than 5 mg/dL with positive direct Coombs test

Neonatal Management of Rh HDN

1. Immediate assessment: Cord blood for blood group, Rh type, DAT, hemoglobin, TSB
2. Intensive phototherapy: Start immediately if cord bilirubin elevated or DAT positive. High-irradiance LED units from HEAMAC phototherapy rental ensure effective treatment initiation
3. IVIG: 0.5-1 g/kg IV if TSB rising rapidly despite intensive phototherapy
4. Exchange transfusion: If TSB reaches exchange threshold despite phototherapy and IVIG
5. Monitor for late anemia: Hemoglobin at 2, 4, 6, and 8 weeks post-discharge; many infants with Rh HDN develop late hyporegenerative anemia requiring erythropoietin or transfusion

Indian Public Health Context

Coverage Gaps

Despite the proven efficacy and availability of anti-D in India, coverage remains suboptimal due to several factors:

• Home deliveries: 18% of Indian deliveries occur at home (NFHS-5); these women are unlikely to receive postnatal anti-D
• First-trimester events: Many abortions, miscarriages, and ectopic pregnancies in India are managed without anti-D due to lack of awareness
• Rural PHC limitations: Anti-D may not be stocked or cold-chain maintained at primary health centers
• Cost barriers: In private settings, INR 2,000-4,000 per dose can be a barrier for families from lower economic strata
• Documentation gaps: Rh status from previous pregnancies may not be documented, leading to missed prophylaxis opportunities

Government Initiatives

Several Indian state governments have included anti-D prophylaxis in maternal health programs. The Janani Suraksha Yojana (JSY) and Pradhan Mantri Surakshit Matritva Abhiyan (PMSMA) frameworks provide opportunities for integrating universal anti-D coverage for Rh-negative mothers. The Indian Society of Blood Transfusion and Immunohematology (ISBTI) has advocated for mandatory Rh typing at first antenatal registration.

Key Clinical Pearls for Indian Practice

1. Never assume immunity: Anti-D prophylaxis should be offered to every unsensitized Rh-negative mother, even in subsequent pregnancies. Previous anti-D doses do not confer lasting immunity
2. 72-hour window is ideal, not absolute: While anti-D is most effective within 72 hours, it may provide partial protection up to 28 days after the sensitizing event. Late administration is better than no administration
3. Anti-D does not help already sensitized mothers: Once anti-D antibodies are detected on ICT, prophylaxis is ineffective. Management shifts to monitoring fetal well-being and preparing for neonatal treatment
4. Father's Rh testing: If the father is Rh-negative, the baby will also be Rh-negative, and anti-D is unnecessary. This can save resources in appropriate cases
5. Postpartum follow-up: Ensure neonatal jaundice surveillance for babies born to Rh-negative mothers, even those who received anti-D, as prophylaxis is not 100% effective

Prevention Message: Anti-D immunoprophylaxis is one of the most effective and cost-effective preventive interventions in medicine. Every rupee spent on anti-D prevents thousands of rupees in NICU costs for treating severe Rh hemolytic jaundice, not to mention the immeasurable value of preventing kernicterus and its lifelong neurological consequences. HEAMAC supports this preventive approach while ensuring effective phototherapy access when treatment is needed.